Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells

Seung Hun Kim, Wen Hsing Wang, Jing Ping Wang, Chang Heng Hsieh, Kang Fang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: The prevalent human hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality. The small molecular weight triepoxide derivative, 1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one-1,3,5-tri-(oxiranylmethyl) (teroxirone), has been proved effective against the proliferation of lung cancer cells. The purpose is to further examine if teroxirone regulate growth and metastatic potential of HCC cells with aims at disclosing more of the reaction mechanisms. Main methods: Measurements of cell viability and flow cytometry were conducted to test sensitivities of teroxirone against HCC cells. The signaling pathway leading to apoptotic death was unraveled by Western blotting analysis. The metastatic progression was evaluated by cell-based phenotype assay that included migration, invasion, gelatin zymography and wound assay. The in vivo drug efficiency was done in immune-deficient mice with the established xenograft tumors. Key findings: Teroxirone inhibited growth of HCC cells, but not hepatic cells. The drug induced apoptosis in HCC cells bearing mutant p53. Pretreatment of caspase-3 inhibitor restored cell viabilities by suppressing extrinsic pathway-mediated cell death. More experiments suggested that sub-apoptotic concentrations of teroxirone mitigated migration, invasion and wound healing of HCC cells. The drug reduced growth of the xenograft tumors as established in animal models by activating apoptotic death. Significance: The findings asserted that teroxirone is an eligible addition to the existing options as an anticancer agent to eliminate HCC.

Original languageEnglish
Pages (from-to)997-1008
Number of pages12
JournalBiomedicine and Pharmacotherapy
Volume99
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

teroxirone
Hepatocellular Carcinoma
Growth
Heterografts
Cell Survival
Pharmaceutical Preparations
Neoplasms
Triazines
Caspase Inhibitors
Gelatin
Caspase 3
Antineoplastic Agents
Wound Healing
Hepatocytes
Lung Neoplasms
Flow Cytometry
Cell Death
Animal Models
Molecular Weight
Western Blotting

Keywords

  • Apoptosis
  • Extrinsic pathway
  • Human hepatocellular carcinoma
  • Metastasis
  • Teroxirone
  • Xenograft tumors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. / Kim, Seung Hun; Wang, Wen Hsing; Wang, Jing Ping; Hsieh, Chang Heng; Fang, Kang.

In: Biomedicine and Pharmacotherapy, Vol. 99, 01.03.2018, p. 997-1008.

Research output: Contribution to journalArticle

Kim, Seung Hun ; Wang, Wen Hsing ; Wang, Jing Ping ; Hsieh, Chang Heng ; Fang, Kang. / Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. In: Biomedicine and Pharmacotherapy. 2018 ; Vol. 99. pp. 997-1008.
@article{44f32541a61c42379a44f2be72b091a5,
title = "Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells",
abstract = "Aims: The prevalent human hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality. The small molecular weight triepoxide derivative, 1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one-1,3,5-tri-(oxiranylmethyl) (teroxirone), has been proved effective against the proliferation of lung cancer cells. The purpose is to further examine if teroxirone regulate growth and metastatic potential of HCC cells with aims at disclosing more of the reaction mechanisms. Main methods: Measurements of cell viability and flow cytometry were conducted to test sensitivities of teroxirone against HCC cells. The signaling pathway leading to apoptotic death was unraveled by Western blotting analysis. The metastatic progression was evaluated by cell-based phenotype assay that included migration, invasion, gelatin zymography and wound assay. The in vivo drug efficiency was done in immune-deficient mice with the established xenograft tumors. Key findings: Teroxirone inhibited growth of HCC cells, but not hepatic cells. The drug induced apoptosis in HCC cells bearing mutant p53. Pretreatment of caspase-3 inhibitor restored cell viabilities by suppressing extrinsic pathway-mediated cell death. More experiments suggested that sub-apoptotic concentrations of teroxirone mitigated migration, invasion and wound healing of HCC cells. The drug reduced growth of the xenograft tumors as established in animal models by activating apoptotic death. Significance: The findings asserted that teroxirone is an eligible addition to the existing options as an anticancer agent to eliminate HCC.",
keywords = "Apoptosis, Extrinsic pathway, Human hepatocellular carcinoma, Metastasis, Teroxirone, Xenograft tumors",
author = "Kim, {Seung Hun} and Wang, {Wen Hsing} and Wang, {Jing Ping} and Hsieh, {Chang Heng} and Kang Fang",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.biopha.2018.01.157",
language = "English",
volume = "99",
pages = "997--1008",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells

AU - Kim, Seung Hun

AU - Wang, Wen Hsing

AU - Wang, Jing Ping

AU - Hsieh, Chang Heng

AU - Fang, Kang

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Aims: The prevalent human hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality. The small molecular weight triepoxide derivative, 1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one-1,3,5-tri-(oxiranylmethyl) (teroxirone), has been proved effective against the proliferation of lung cancer cells. The purpose is to further examine if teroxirone regulate growth and metastatic potential of HCC cells with aims at disclosing more of the reaction mechanisms. Main methods: Measurements of cell viability and flow cytometry were conducted to test sensitivities of teroxirone against HCC cells. The signaling pathway leading to apoptotic death was unraveled by Western blotting analysis. The metastatic progression was evaluated by cell-based phenotype assay that included migration, invasion, gelatin zymography and wound assay. The in vivo drug efficiency was done in immune-deficient mice with the established xenograft tumors. Key findings: Teroxirone inhibited growth of HCC cells, but not hepatic cells. The drug induced apoptosis in HCC cells bearing mutant p53. Pretreatment of caspase-3 inhibitor restored cell viabilities by suppressing extrinsic pathway-mediated cell death. More experiments suggested that sub-apoptotic concentrations of teroxirone mitigated migration, invasion and wound healing of HCC cells. The drug reduced growth of the xenograft tumors as established in animal models by activating apoptotic death. Significance: The findings asserted that teroxirone is an eligible addition to the existing options as an anticancer agent to eliminate HCC.

AB - Aims: The prevalent human hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality. The small molecular weight triepoxide derivative, 1,3,5-triazine-2,4,6(1H,3H,5H)-tri-one-1,3,5-tri-(oxiranylmethyl) (teroxirone), has been proved effective against the proliferation of lung cancer cells. The purpose is to further examine if teroxirone regulate growth and metastatic potential of HCC cells with aims at disclosing more of the reaction mechanisms. Main methods: Measurements of cell viability and flow cytometry were conducted to test sensitivities of teroxirone against HCC cells. The signaling pathway leading to apoptotic death was unraveled by Western blotting analysis. The metastatic progression was evaluated by cell-based phenotype assay that included migration, invasion, gelatin zymography and wound assay. The in vivo drug efficiency was done in immune-deficient mice with the established xenograft tumors. Key findings: Teroxirone inhibited growth of HCC cells, but not hepatic cells. The drug induced apoptosis in HCC cells bearing mutant p53. Pretreatment of caspase-3 inhibitor restored cell viabilities by suppressing extrinsic pathway-mediated cell death. More experiments suggested that sub-apoptotic concentrations of teroxirone mitigated migration, invasion and wound healing of HCC cells. The drug reduced growth of the xenograft tumors as established in animal models by activating apoptotic death. Significance: The findings asserted that teroxirone is an eligible addition to the existing options as an anticancer agent to eliminate HCC.

KW - Apoptosis

KW - Extrinsic pathway

KW - Human hepatocellular carcinoma

KW - Metastasis

KW - Teroxirone

KW - Xenograft tumors

UR - http://www.scopus.com/inward/record.url?scp=85041659495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041659495&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2018.01.157

DO - 10.1016/j.biopha.2018.01.157

M3 - Article

VL - 99

SP - 997

EP - 1008

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -